Add Lenacapavir to Your List of PrEP Recommendations

September 2025

Lenacapavir (Yeztugo) is the first TWICE-YEARLY subcutaneous injectable option for HIV pre-exposure prophylaxis (PrEP).

Lenacapavir is a long-acting HIV capsid inhibitor. It joins the oral, daily PrEP options emtricitabine/tenofovir DISOPROXIL fumarate (Truvada) and emtricitabine/tenofovir ALAFENAMIDE (Descovy)...and the every-two-month IM injectable option, cabotegravir (Apretude).

In studies comparing injectable lenacapavir with emtricitabine/ tenofovir DISOPROXIL fumarate, either option is shown to be over 99% effective in preventing HIV...when taken as prescribed.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote